eligibility_summary
Adults (≥18) with pathologically confirmed, treatment‑naïve ES‑SCLC (prior limited stage allowed if DFS ≥6 mo), measurable disease (RECIST 1.1), tumor tissue, ECOG 0–1, adequate organs, WOCBP contraception. Exclude prior ICI/topo‑I, recent systemic/RT or unresolved ≥G2 AEs, live vaccine, immunodeficiency/steroids, CNS mets only if asymptomatic/stable, autoimmune/ILD/infection/IBD, HBV/HCV/HIV, other active cancer, pregnancy, allogeneic transplant, unrecovered surgery, serious psychiatric issues.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Phase II single-arm first-line study in extensive-stage SCLC. Induction: carboplatin (platinum cytotoxic, forms DNA crosslinks) + etoposide (cytotoxic topoisomerase II inhibitor) + pembrolizumab (anti–PD-1 monoclonal antibody checkpoint inhibitor). Maintenance: pembrolizumab + sacituzumab govitecan (TROP-2–targeted antibody–drug conjugate delivering SN-38, a topoisomerase I inhibitor). Targets/pathways: tumor DNA damage/repair via platinum adducts, DNA topology via Topo II (etoposide) and Topo I (SN-38), PD-1/PD-L1 immune checkpoint to reactivate tumor-specific T cells, TROP-2 on tumor cells to selectively deliver SN-38. Overall strategy: combine chemo-induced cytotoxicity with checkpoint blockade and ADC-mediated targeted cytotoxic delivery.